Novel Molecules to Treat Chronic Central Nervous System Toxoplasmosis

Abstract

A major challenge in treating toxoplasmosis in immunocompromised patients is lack of therapeutic agents to clear chronic infection and stop the recrudescence of infection after therapy. CDKP1 has emerged as a novel target for treating chronic infections and eliminating latent bradyzoites in the brain. In a mouse model of toxoplasmosis, pyrazolopyrimidine inhibitors of Toxoplasma gondii CDPK1 demonstrated in vitro and in vivo efficacy.